Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Effect of Medical Interventions in Insulin Resistance on Prevalence of Abnormal Glucose Tolerance
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02502344
- Locations
- 🇨🇳
BEI JING Tsinghua Changguang Hospital, Beijing, Beijing, China
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02501850
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
Effect of Dapagliflozine on Systemic and Renal Endothelial Function
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2015-07-17
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT02501616
- Locations
- 🇰🇷
Boramae medical center, Seoul, Korea, Republic of
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
- Conditions
- Non-Alcoholic Fatty Liver DiseasePolycystic Ovary SyndromeMetabolic Syndrome
- Interventions
- Drug: PlaceboDrug: Metformin
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 6
- Registration Number
- NCT02500147
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Heart Rate Variability in Response to Metformin Challenge
- Conditions
- FibromyalgiaMitochondrial DiseasesMovement DisordersDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2018-01-03
- Lead Sponsor
- Woodinville Psychiatric Associates
- Target Recruit Count
- 61
- Registration Number
- NCT02500628
- Locations
- 🇺🇸
Woodinville Psychiatric Associates, Woodinville, Washington, United States
Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2016-05-19
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 166
- Registration Number
- NCT02498522
- Locations
- 🇪🇬
Faculty of Medicine, Ain Shams University, Cairo, Al Qahirah, Egypt
Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 15
- Registration Number
- NCT02497313
- Locations
- 🇩🇰
Center for Diabetes Research, Herlev-Gentofte Hospital, Hellerup, Denmark
LIpitor and biGuanide to Androgen Delay Trial
- Conditions
- Prostate Cancer
- Interventions
- Drug: Placebo (corresponding to metformin)Drug: MetforminDrug: Placebo (corresponding to atorvastatin)Drug: Atorvastatin
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- University Health Network, Toronto
- Registration Number
- NCT02497638
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
- Conditions
- Renal Cell CarcinomaHereditary LeiomyomatosisRenal Cell Cancer
- Interventions
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 7
- Registration Number
- NCT02495103
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)
- Conditions
- Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 176
- Registration Number
- NCT02492763
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.